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Fragile X-associated primary ovarian insufficiency (FXPOI) is due to an X-linked mutation
that results from the expansion of a CGG repeat sequence located in the 5′ untranslated
region of the FMR1 gene (premutation, PM). About 20% of women who carry the PM
have cessation of menses before age 40, a clinical condition known as premature ovarian
failure (POF). This leads to a 20-fold increased risk over women in the general population.
Thus, this single gene mutation has a major effect on reducing a woman’s reproductive
life span. Based on survival analysis of about 1300 women, we showed that the mean
age at menopause among PM carriers is reduced compared with noncarriers, even after
removing women who reported POF. This suggests that the majority of women with the
PM, not just a subset, experience ovarian insufficiency earlier than noncarriers. To better
understand the underlying mechanism of the PM and to identify genes that modify the
variable expressivity of FXPOI, we conducted two pilot studies. The first focused on five
common variants known to reduce age at menopause. We genotyped these SNPs in 72
women with a PM who experienced menopause and found a significant association with
the total SNP risk burden and age at menopause. This suggests that these SNPs influence
onset of FXPOI, after adjusting for the effect of the PM allele. In the second approach, we
conducted whole genome sequencing on 10PM carriers, five with onset of FXPOI prior
to age 30 and five who experienced menopause after age 47 years. Although only a pilot
study, we describe our preliminary approach to identify potential variants that may play a
role in modifying onset of FXPOI and potentially play a role in idiopathic primary ovarian
insufficiency. The overarching goal of both approaches is to identify predictor variants
that may identify women predisposed to early onset FXPOI and to further identify genes
involved in defining a woman’s reproductive life span.
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INTRODUCTION
Fragile X-associated primary ovarian insufficiency (FXPOI) is
one of the disorders caused by the expansion of a CGG repeat
sequence located in the 5′ untranslated region (UTR) of the X-
linked FMR1 gene. About 20% of women who carry an allele
with 55 to 200 unmethylated CGG repeats [termed premutation
(PM) allele] develop hypergonadotropic hypogonadism and cease
menstruating before age 40. This clinical condition, also known
as premature ovarian failure (POF), occurs in about 1% of the
general population. Thus, carrying the PM greatly increases the
risk for POF (Sherman, 2000; De Caro et al., 2008; Sullivan et al.,
2011).
The term primary ovarian insufficiency (POI) includes both
POF and occult indicators of ovarian function, such as increased
levels of follicle stimulating hormone (FSH) and decreased lev-
els of anti-Müllerian hormone (AMH). As this entire spectrum,
including the altered hormone profile, is seen among women with
the PM (Murray et al., 2000; Hundscheid et al., 2001; Welt et al.,
2004; Sullivan et al., 2005; Rohr et al., 2008; Spath et al., 2011a),
the term “FXPOI” is well suited (Welt, 2008).
Very little is known about the mechanisms leading to FXPOI.
The other clinically significant form of the FMR1 expansion
mutation is the full mutation (FM). This mutation leads to fragile
X syndrome, an inherited form of intellectual and developmental
disabilities. The FM is defined as an allele with >200 methy-
lated CGG repeats and causes the silencing of the FMR1 gene.
Consequently, no or little protein product (FMRP) is made in
hemizygous male carriers and reduced amounts in heterozy-
gous female carriers. Early on, it was shown that women who
carry the FM are not at increased risk for ovarian dysfunction
(Schwartz et al., 1994; Allingham-Hawkins et al., 1999). This
important observation indicates that reduction of FMRP does
not underlie the etiology of ovarian dysfunction. Instead, some
characteristic of the PM allele is the culprit. There are impor-
tant molecular consequences of the PM: with increasing repeat
length, there is increasing FMR1 transcript levels and decreasing
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FMRP levels (Kenneson et al., 2001; Allen et al., 2004; Garcia-
Alegria et al., 2007; Tassone et al., 2007; Peprah et al., 2010).
Many have postulated that FMR1 mRNA toxicity may underlie
FXPOI, as is the case for the other PM-associated disorder, fragile
X-associated tremor/ataxia syndrome (FXTAS) (Hagerman et al.,
2001).
Not all women with the PM experience POF, only about 20%.
Four factors have been examined to try to explain the incom-
plete penetrance of POF among PM carriers: CGG repeat length,
skewed X-chromosome inactivation (XCI), smoking and back-
ground genes. First, there is a strong non-linear association of the
penetrance of POF with repeat number: women with mid-range
PM repeats (approximately 80–100 repeats) have the highest risk
for POF. Carriers of both smaller and larger PM repeat alleles also
have an increased risk of POF compared to the general popula-
tion, but not to the same extent as mid-range PM repeat carriers
(Sullivan et al., 2005; Ennis et al., 2006; Allen et al., 2007; Tejada
et al., 2008; Spath et al., 2011b). Second, skewed XCI was con-
sidered as potentially modifying the risk of severity of FXPOI,
as FMR1 is located on the X chromosome. However, no study
has found evidence for skewed XCI based on samples from fresh
blood among PM carriers (Murray et al., 2000; Sullivan et al.,
2005; Bione et al., 2006; Tejada et al., 2008; Rodriguez-Revenga
et al., 2009; Spath et al., 2010). Assuming that XCI in blood
can be used as a proxy for the correct target tissue, one possi-
ble explanation for this observation is that the toxic effect of the
PM acts during a stage in development when both X chromo-
somes are active. Third, smoking, an important modifiable risk
factor known to reduce age at menopause, has been shown to have
the same effect on women with the PM as it does on noncarriers
(Allen et al., 2007; Spath et al., 2011b).
Lastly, we have indirect evidence that the risk of POF depends
not only on the PM allele, but also on other background genes. In
Hunter et al. (2008), we used a random-effects Cox proportional
hazards model to analyze age at menopause on 680 women drawn
from 225 families who had a history of fragile X syndrome and
321 women from 219 families drawn from the general population.
We found the presence of a statistically significant residual addi-
tive genetic effect after adjustment for FMR1 repeat length and
other covariates (p-values ranging between 0.0002 and 0.0027,
depending on the parameterization of FMR1 repeat size and def-
inition of age at menopause). Using a combined data set from
our U.S. study and one from the Netherlands consisting of 1068
women, we found that the mean age at menopause among first
degree relatives as a predictor of age at menopause was statisti-
cally significant only among noncarriers, not among PM carriers
once adjusting for PM repeat length and smoking (Spath et al.,
2011b).
This indirect evidence for modifying/background variants is
fortified by recent GWAS studies that have identified genetic vari-
ants associate with age at menopause (He et al., 2009; Stolk et al.,
2009, 2012; Shen et al., 2013). Perry et al. (2013) also showed that
these same variants were associated with age atmenopause among
women with early menopause (age 41–45). These results sup-
port the hypothesis that early menopause and POFmay represent
the tail of the menopause distribution and thus have overlapping
etiology.
In addition, studies showing the molecular and biological con-
sequences of the PM provide a basis for choosing candidate genes
and pathways on which focus genetic studies. For example, pro-
teins known to bind to the CGG track found in FMR1mRNA and
their interacting partners are excellent candidate genes in which
to study genetic variants [e.g., Pur α, hnRNP A2/B1, Sam68,
miRNA processing complex DROSHA-DGCR8 (Jin et al., 2007;
Sofola et al., 2007; Sellier et al., 2010, 2013)]. Another category
includes genes in pathways that have been found to be altered
in the FXPOI mouse model: the leutenizing hormone (LH)-
mediated pathway and the mTOR signaling network (Lu et al.,
2012). In this FXPOI model, LH-induced ovulation related gene
expression was specifically altered. As well, there was reduced
phosphorylation of Akt and mTOR proteins.
In summary, little is known about the etiology of FXPOI.
Here we took three approaches to begin to determine the influ-
ence of modifying genetic variants on the onset of FXPOI. First,
we examined the distribution of age at menopause among PM
carriers to determine whether only a subset of PM carriers are
affected with FXPOI (incomplete penetrance) or whether the age
at menopause distribution is decreased among all PM carriers
(variable expressivity). Next, we examined the association of five
common SNPs known to reduce age at menopause in the general
population among PM carriers who had experienced menopause.
Lastly, we conducted an exploratory candidate gene study using
whole genome sequencing (WGS) among five PM carriers with
early onset FXPOI and five PM carriers with age at menopause
at the typical time as controls to identify possible variants that
influence onset of FXPOI.
MATERIALS AND METHODS
STUDY POPULATION
The study population analyzed for the three questions addressed
extends that reported in Sullivan et al. (2005) and Allen et al.
(2007). All participants were recruited using the same protocol.
Briefly, study participants were ascertained from families with a
history of FXS to enrich the sample with varying repeat lengths as
well as from the general population (see Sullivan et al., 2005 for
a review of ascertainment protocols). Once a proband was identi-
fied, female relatives were also invited to participate in the study.
Participants were aged 18–92 and had English as their primary
language. All participants were asked to complete a reproduc-
tive history questionnaire and provide a biological sample, either
buccal or blood, for repeat-length determination. Subsets of this
study population were used for each question addressed and
are defined in more detail in Results. The protocols and con-
sent forms for ascertainment were approved by the Institutional
Review Board at Emory University.
DATA COLLECTION AND VARIABLE DEFINITIONS
We administered the reproductive history questionnaire to obtain
demographic information including age at interview, date of
birth, ethnic/racial group and education. Information on poten-
tial confounders and effect modifiers was collected and included
smoking (1, ever smoked on a regular basis; 0, otherwise)
and hormone use (1, current hormone use; 0, otherwise). We
obtained menstrual cycle history including age at menarche and
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age and date of last menstrual period. If the date of last menstrual
period was more than 2 months prior to the interview, we iden-
tified the cause of menses cessation. Women completed a brief
medical history concerning disorders associated with ovarian dys-
function and co-morbid disorders related to reproductive aging.
Although all questions were started with “Has a doctor ever told
you that you had. . .?” all conditions were based on self-report.
Medical records were not obtained to verify fertility problems or
medical disorders. We defined age at menopause as the cessation
of menses for at least 1 year.
FMR1 REPEAT LENGTH DETERMINATION
All participants were asked to provide a biological sample, either
buccal or blood. DNA was extracted using the Qiagen QiAmp
DNA Blood Mini Kit (Valencia, CA). A fluorescent-sequencer
method is used to determine FMR1 CGG repeat length (Meadows
et al., 1996). Briefly, fluorescent-labeled primers are used to
polymerase chain reaction amplify across the repeat region
and the resulting product is run on an automated sequencer.
Repeat lengths up to 90 can be determined with this method.
In the event that a single band was detected in females, indi-
cating either homozygous status or the presence of a larger
repeat band from the second allele, an alternative polymerase
chain reaction-based, hybridization technique was used (Brown
et al., 1993). For heterozygous females, the CGG repeat length
from the largest repeat allele was used to define FMR1 repeat
length.
COMMON SNP GENOTYPING
All individuals were genotyped for rs16991615, rs2517388,
rs2277339, rs11668344, and rs365132 using predesigned TaqMan
assays purchased from Applied Biosystems (Foster City, CA).
Briefly, reactions were set up in a total reaction volume of 5 ul
including 1× TaqMan Genotyping Master Mix, 1× TaqMan SNP
Genotyping Assay probe, and 10 ng of DNA. PCR amplifica-
tion was performed using Applied Biosystems’ TaqMan 7900HT
sequence detection software (SDS). PCRwas performed by an ini-
tial activation of AmpliTaq gold (95◦C for 10min) followed by
40 cycles of denaturing (95◦C for 15 s) and annealing/extension
(60◦C for 1min). Alleles were automatically determined by the
SDS software.
WHOLE GENOME SEQUENCING (WGS) AND ANNOTATION
PCR-free paired end libraries were manually generated from
500 ng to 1 ug of gDNA using a modified version of TruSeq
DNA v2 Sample Preparation kits (Catalog # FC-121-2001). DNA
fragmentation was performed with a Covaris LE220. After frag-
mentation and end repair, libraries were manually size-selected to
approximately 300 bp using bead-based size selection (Agencourt
AMPure XP #A63881). Following size selection, libraries were A-
tailed, and ligated with sequencing adapters before proceeding to
library QC. Final libraries were assessed using a Caliper GX and
quantified by qPCR on the Roche LightCycler 480.
Cluster generation was performed with the Illumina cBot
and the TruSeq Paired End Cluster Kit (v3). Flowcells (v3) were
sequenced on the Illumina HiSeq2000 platform with a 100 bp
paired-end read protocol and TruSeq (v3) SBS chemistry. Read
data were aligned and variants called using the CASAVA1.8.2
pipeline.
Each genome was annotated using version 2.6 of Knome’s
proprietary annotation engine kGAP (Knome Genome Analysis
Pipeline, Knome Inc., Cambridge, MA). kGAP annotates all
classes of substitution and small indel variant calls (as well as
reference-matching sites and no calls) and assesses whether a
call is novel or known in comparison to dbSNP135 (http://www.
ncbi.nlm.nih.gov/projects/SNP/). Allele frequency information
from HapMap3 (Altshuler et al., 2010) is also incorporated
(additional allele frequency data are applied post-kGAP, see
below). For gene context, kGAP considers variants with respect
to ENSEMBL (Release 66) gene models. kGAP uses the com-
bined SIFT/PolyPhen2 module of Condel to predict the dele-
teriousness of a reference-mismatching variant (Gonzalez-Perez
and Lopez-Bigas, 2011). kGAP also reports conservation scores
based on PhastCons scores for eutherian mammals (Siepel et al.,
2005). Phenotype annotations and known literature associations
applied by kGAP originate from HGMD (www.hgmd.org) or
from Knome’s own custom manual curation. For variant sites
that overlap multiple genes, annotations are reported for all; how-
ever, prioritization is given to the gene model with the greatest
predicted functional effect at the protein level.
IDENTIFYING VARIANTS FROMWHOLE GENOMES
Knome’s proprietary kVariants software allows for the selection
of the subset of kGAP-annotated variants that fit a specified
mode of inheritance and/or etiology (i.e., somatic variants in
tumor/normal comparisons, etc.). Within this framework, we
identified confidently called variants in several candidate gene
lists. Calling parameters required a site pass GATK filters in
all samples (Quality = 30.0; Quality/depth = 5.0; Homoplasy
run < 6; Strand bias < −0.10). Coding variants that matched
the search criteria were then filtered to remove sites in known
segmental duplications and to eliminate variants outside of
RefSeq exons. These filtered variant lists were then further anno-
tated to include allele frequency information from the Exome
Variant Server (http://evs.gs.washington.edu/EVS/) and the 1000
Genomes Project (http://www.1000genomes.org/).
An overview of the sequencing experiment by study sample is
provided in Supplement Table 1.
RESULTS
AGE AT MENOPAUSE DISTRIBUTION: EVIDENCE FOR VARIABLE
EXPRESSIVITY
We examined the age at menopause distributions of PM carriers,
including and excluding those who reported POF. This was done
to test the hypothesis that there is a subset of women who are
at risk for ovarian dysfunction (i.e., incomplete penetrance). The
alternative hypothesis is that all women who carry the PM are at
risk for some degree of ovarian dysfunction, manifesting as an
overall earlier age at menopause (variable expressivity). Although
these hypotheses are not necessarily mutually exclusive, they may
provide insight into the types of modifying genes that might be
important in understanding FXPOI.
We defined age at menopause as the cessation of menses for
at least 1 year. However, pinpointing the exact age at which
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menopause occurs can be problematic due to the duration of the
transition as well as the common use of hormone medication at
the start of menopause symptoms. Here we used self-reported
age at menopause without taking into account hormone use
history (Scheme I in Sullivan et al., 2005). We think this may
be conservative, as hormone use during transition may mask
menopause and thus lead a woman to report a later age at
menopause.
Among those who reported experiencing menopause, the
unadjusted mean age at menopause was lowest among women
who carried the mid-range PM length, as reported previously
(Sullivan et al., 2005; Allen et al., 2007). When women who
reported POF were excluded, the mean age at menopause
increased, as expected (Table 1). To test whether the differences in
mean menopause age between PM carrier groups and noncarri-
ers were statistically significant, we estimated hazard ratios using
a Cox proportional hazard model. Age at censoring for women
who had not reported experiencing menopause was defined as
age at interview. For those who had other reasons for cessation
of menses (e.g., hysterectomy, eating disorder, etc.) were censored
at age of last menses. We included the following covariates in
the model: age at interview, racial/ethnic group, body mass index
(BMI) and ever smoked. For each PM repeat group, the haz-
ard ratio was significantly different from one, indicating a higher
risk for reaching menopause earlier among those with the PM
compare with noncarriers (Table 2).
COMMON VARIANTS: INFLUENCE ON AGE AT MENOPAUSE AMONG
PM CARRIERS
To examine the influence of common variants that are known to
be associated with age at menopause, we chose five SNPs with
the largest effect size found among women who experience nor-
mal age a menopause (Stolk et al., 2012) (Table 3). These five
SNPs were also found to influence age at menopause among those
with early menopause (Perry et al., 2013). All women selected for
this study sample self-reported as Caucasian and had experienced
menopause/FXPOI. Because this was a preliminary study with a
small sample size (n = 72, Table 4), we conducted only one pri-
mary statistical test that combined the effect of all five SNPs. To
do these we created a quantitative variable (Total SNP Risk) that
equaled the sum over the five SNPs of the number of risk alle-
les per SNP multiplied by the effect size per allele, the effect size
being that estimated from themeta-analyses of women experienc-
ing typical age at menopause (Stolk et al., 2012; Perry et al., 2013).
We then conducted linear regression with age at menopause as the
outcome variable and repeat size and Total SNP Risk as predictor
variables. Repeat size was parameterized as a continuous variable
with the square of repeat size added in the model to account for
the non-linear effect of the PM size allele. We found that Total
SNP Risk, or the weighted sum of the SNP genotypes, was signif-
icantly associated with age at menopause after adjusting for effect
of PM repeat length (Table 5). In this model, it explained about
7% of the variance in age at menopause (p = 0.03).
Table 2 | Hazard ratios estimated from Cox proportion hazard model,
adjusting for age at interview, race/ethnicity, ever smoked and BMI
as covariates.
Repeat group Including women Excluding women
with POF with POF
Hazard ratio p-value Hazard ratio p-value
(PM repeat vs. (PM repeat vs.




2.4 <0.0001 2.3 <0.0001
Mid PM: 80–100
repeats
4.1 <0.0001 3.1 <0.0001
High PM: 100–200
repeats
2.5 0.0001 2.2 0.0035
Table 3 | SNPs known to influence age at menopause (data taken
from Stolk et al., 2012 and Perry et al., 2013).





rs16991615 20 5896227 G 0.93 −0.948
rs11668344 19 60525476 G 0.36 −0.416
rs2277339 12 55432336 G 0.10 −0.380
rs365132 5 176311180 G 0.51 −0.287
rs2517388 8 38096889 T 0.83 −0.262
Table 1 | Unadjusted mean age at menopause including and excluding women with POF.
Repeat group Number of women Including women with POF Excluding women with POF
Total Reported Reported Mean age at Unadjusted Mean age at Unadjusted
menopause/POF POF interview ± SD mean age at interview ± SD mean age at
menopause ± SD menopause ± SD
Normal: <55 repeats 694 111 6 43.4 ± 16.0 49.4 ± 4.4 43.3 ± 16.0 49.9 ± 3.8
Low PM: 55–79 repeats 247 70 11 48.1 ± 15.4 45.2 ± 5.8 47.8 ± 15.2 47.1 ± 3.0
Mid PM: 80–100 repeats 350 79 37 43.3 ± 12.8 40.5 ± 8.5 42.1 ± 12.4 46.8 ± 3.6
High PM: 100–200 repeats 113 19 5 39.5 ± 11.5 45.4 ± 6.0 38.9 ± 11.4 48.1 ± 4.4
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Table 4 | Study sample used to examine the association of common
SNPs reported to influence normal age at menopause.
N N with POF Age at menopause
Mean ± SD
Low PM: 55–79 repeats 25 2 45.1 ± 7.2
Mid PM: 80–100 repeats 40 14 40.4 ± 8.2
High PM: 100–200 repeats 7 1 46.0 ± 6.4
Table 5 | Linear regression model showing the significant association
of “Total SNP Risk” variable that sums the weighted genotypes over
five SNPs known to influence age at menopause (see text), adjusting
for variables of PM repeat length.
Predictor B coefficient ± SE Partial R2 p-value
Repeat length −1.650 ± 0.613 0.096 0.009
Square (repeat length) 0.009 ± 0.003 0.095 0.009
Total SNP risk −3.710 ± 1.684 0.067 0.031
CANDIDATE GENE STUDY USING WHOLE GENOME SEQUENCING:
POSSIBLE HINTS FOR FURTHER STUDY
As a preliminary approach to identify potentially deleterious vari-
ants on a genetically susceptible background (i.e., PM allele), we
conductedWGS on five women who carried the PM and had early
onset FXPOI and five PM carriers who experience menopause
after age 47, frequency matched by repeat size (Table 6). All
women self-reported as Caucasian.
We need to preface our results by emphasizing that this pilot
study is obviously limited by the sample size. WGS identified on
average 3 million variants per sample (Supplement Table 1). In a
much larger study, we could interrogate each variant individually
(or by gene or pathway) and ask whether a variant is associated
statistically. However, even in a large study, success of a WGS
study does not come from statistical significance. Instead, the
main purpose of the statistical evaluation is to create a ranking
of variants (or genes or pathways) for further functional stud-
ies. Nevertheless, we present preliminary results, primarily in
candidate genes/pathways, to show the potential of these stud-
ies and perhaps to spark the attention of other investigators who
study POI.
First we examined several categories of candidate genes: (1)
genes involved in age at menopause or ovarian function based
on a review of the literature (referred to as “genes of interest,”
n = 161); (2) miRNAs found to be differentially expressed among
women with POI (n = 13) (Baley and Li, 2012); and, based on the
FXPOImousemodel, (3) genes in themTOR signaling network as
defined by KEGG (n = 64); and (4) genes responsive to the LH-
mediated pathway (n = 6) (Lu et al., 2012) (Supplement Table
2). Among genes involved in age at menopause or ovarian func-
tion, we first examined common (MAF > 1%) non-synonymous
variants that occurred among cases and not controls. We found
28 such variants among the 161 ovarian function genes of inter-
est (Supplement Table 3). The P29S missense variant in MSH5
(8% in general population) has been observed in women with
Table 6 | Study sample for WGS variant discovery.
Study ID Age at Repeat Mean depth
menopause length coverage
CASES
poi1 21 89 40.33
poi2 19 91 37.24
poi3 23 90 39.73
poi4 28 91 43.16
poi5 16 76 36.24
CONTROLS
ctr6 49 90 34.78
ctr7 50 93 38.48
ctr8 50 77 35.59
ctr9 52 90 38.66
ctr10 48 90 34.12
POI (Mandon-Pepin et al., 2008) and occurred in a women (poi2)
whose onset of FXPOI was age 19. Of the six variants found in
multiple cases, none was predicted to change function.
We also identified rare (MAF < 1%) or novel non-
synonymous variants among cases and not controls in our 161
genes of interest. We found 21 variants, with three that are pre-
dicted to change function in the following genes: IGF2R, NBN,
TNFRSF17 (Supplement Table 4).
Among the miRNAs that were reported to be differentially
expressed in POI cases (n = 13) (Baley and Li, 2012), no case-
specific variants were identified. There were four variants among
those 13 miRNAs and all appeared among both cases and controls
(Supplement Table 5).
Findings from the FXPOI mouse model suggested that the
PM allele may disrupt mTOR/AKT signaling and may alter LH-
induced ovulation related gene expression (Lu et al., 2012). Thus,
we examined variation in the 64 genes in the KEGG mTOR sig-
naling pathway (hsa04150) to play a role in this signaling network
and in the LH-mediated pathway (Supplement Table 6). We iden-
tified common case-specific non-synonymous variants in three
genes: PIK3CD, TSC2, and EREG. Interestingly, EREG was one of
themRNAs shown to be down-regulated in FXPOImice (Lu et al.,
2012). We also found four rare case-specific non-synonymous
variants in the following genes: PIK3CB, PIK3CG, CAB39l, TSC2
[Note that the novel variant in TSC2 is the same variant that is
listed among the genes of interest (Supplement Table 2)].
Lastly, we took a more agnostic approach and we asked
whether there were any genes enriched for variants among
cases compared with controls. To do this, we identified non-
synonymous variants that were specific to cases or to controls.
We then selected genes with at least five case-specific variants
and where there were at least twice as many case-specific vari-
ants as control-specific variants. We then filtered out genes that
are known to harbor frequent variants due to extreme length,
relaxed selection, or likely false positives due to the presence
of a cryptic paralog. In all, there were 25 genes enriched for
variants in cases (Supplement Table 7). Among these, two are
interesting in this context: (1)AKAP1 encodes an A-kinase anchor
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proteins that anchors PKA to mitochondria; correct localiza-
tion of PKA is required for oocyte maturation (Newhall et al.,
2006; Nishimura et al., 2013) and (2) GREB1 encodes an early
response gene in the estrogen-regulated pathway and is involved
in hormone-dependent breast cancer cell growth (Rae et al.,
2005).
DISCUSSION
FXPOI is the leading known cause of POI and can be iden-
tified through genetic testing, prior to symptoms of POI.
Approximately 11% of women with familial POF and about 3%
of those with isolated POF carry the PM and are diagnosed with
FXPOI (Murray et al., 1998; Marozzi et al., 2000; Mallolas et al.,
2001; Bussani et al., 2004). PM carrier frequency in the gen-
eral population is estimated at 0.40–0.67% of women (Cronister
et al., 2008; Seltzer et al., 2012) The course of FXPOI is vari-
able with respect to severity. Currently, women identified with
the PM provide one of few opportunities to examine modify-
ing genetic variants and environmental factors in the context of a
single gene mutation that increases severity of POI. The findings
from the FXPOImodel are highly likely to translate to other forms
of POI.
The FMR1 PM allele significantly reduces a woman’s repro-
ductive life span, especially among those who carry alleles with
about 80–100 repeats. Not only does this major gene effect
interfere with fertility, the most immediate and significant conse-
quence of diminished ovarian function, but it also increases the
risk for other disorders related to hypoestrogenism at an early
age. These include an increased risk for low bone density, ear-
lier onset osteoporosis and fractures (Gallagher, 2007), impaired
endothelial function (Kalantaridou et al., 2004), earlier onset of
coronary heart disease (Atsma et al., 2006), and increased car-
diovascular mortality and overall mortality (e.g., Jacobsen et al.,
2003; Mondul et al., 2005). Also, women with POI are reported
to have more symptoms of psychological distress than women
with normal ovarian function (e.g., van der Stege et al., 2008).
Hypoestrogenism has cognitive consequences as well. Estrogen is
a neuro-protective agent which plays an important role in brain
functioning, and changes in estrogen levels during aging are asso-
ciated with reduced cognitive function and an increased risk of
Alzheimer’s disease (Janicki and Schupf, 2010). For women who
carry the PM and, thus, are at risk for the neurodegenerative
disorder, FXTAS, early estrogen deficiency could be particularly
detrimental. Thus, identifying genes that predispose to early onset
FXPOI is clinically significant.
In this preliminary report, we chose two approaches to iden-
tify genes that may explain the variable expressivity of FXPOI. We
first choose genetic variants known to reduce age at menopause
in women who experience menopause at the typical age (Stolk
et al., 2012) and in those who experience early menopause (Perry
et al., 2013). We found preliminary evidence that the “burden” of
these five SNPs was statistically significantly associated with age
at menopause among women who carry the PM, after adjusting
for repeat size. However, our sample size was limited and a repli-
cation study needs to be conducted before strong conclusions can
be drawn. Nevertheless, these findings suggest that genetic vari-
ants that explain some of the heritability of age at menopause
may also influence ovarian function on the background of amajor
gene effect of the PM.
Advances on several technical and analytical fronts have made
WGS a viable approach. It allows a comprehensive way to iden-
tify the full spectrum of genetic variation. We took this approach
to compare the variation among women in the extreme tails of
the age of onset distribution for FXPOI. Although we were only
able to study five women in each tail of the age distribution in
this pilot study, it is a start to an important approach to iden-
tify rare variants that may influence the severity of FXPOI and
potentially identify novel genes involved in idiopathic POI. The
Supplement Tables generated from this results list many case-
specific potentially damaging variants that might complement
studies of other investigators. However, on there own, no con-
clusions can be drawn. Clearly a larger study is needed to further
delineate a list of candidate variants and pathways, followed by
functional studies to confirm that such variants disrupt ovarian
function.
AUTHOR CONTRIBUTIONS
Emily G. Allen was involved in the study design, data acquisition
and led the data analysis. Wendy E. Grus conducted the bioin-
formatic analyses to prioritize genetic variants from the whole
genome sequencing experiment. Sarayu Narayan was involved in
the sample preparation, SNP genotyping, and performing the
association studies of the SNP data set. Whitney Espinel was
involved in the analysis of the age at menopause to examine vari-
able expressivity of FXPOI. Stephanie L. Sherman was involved in
the study design and implementation. All were involved in results
interpretation and writing of the manuscript.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Stephen Warren for provid-
ing the funds for the whole genome sequencing study from the
Emory’s Genetics Discovery Fund. The data and bio-repository
on women with the premutation was previously supported by
NIH R01 HD29909. The Emory Integrated Genomics Core con-
ducted the SNP genotyping and we thank Malania Wilson for her
oversight.
SUPPLEMENTARY MATERIAL




Allen, E. G., He, W., Yadav-Shah, M., and Sherman, S. L. (2004). A study of the
distributional characteristics of FMR1 transcript levels in 238 individuals.Hum.
Genet. 114, 439–447. doi: 10.1007/s00439-004-1086-x
Allen, E. G., Sullivan, A. K., Marcus, M., Small, C., Dominguez, C., Epstein,
M. P., et al. (2007). Examination of reproductive aging milestones among
women who carry the FMR1 premutation. Hum. Reprod. 22, 2142–2152. doi:
10.1093/humrep/dem148
Allingham-Hawkins, D. J., Babul-Hirji, R., Chitayat, D., Holden, J. J., Yang, K.
T., Lee, C., et al. (1999). Fragile X premutation is a significant risk factor for
premature ovarian failure: the International Collaborative POF in Fragile X
study–preliminary data. Am. J. Med. Genet. 83, 322–325.
Altshuler, D. M., Gibbs, R. A., Peltonen, L., Altshuler, D. M., Gibbs, R. A., Peltonen,
L., et al. (2010). Integrating common and rare genetic variation in diverse
human populations. Nature 467, 52–58. doi: 10.1038/nature09298
Frontiers in Genetics | Genetic Disorders August 2014 | Volume 5 | Article 260 | 6
Allen et al. Genetic modifiers of FXPOI
Atsma, F., Bartelink, M. L., Grobbee, D. E., and van der Schouw, Y. T. (2006).
Postmenopausal status and early menopause as independent risk factors
for cardiovascular disease: a meta-analysis. Menopause 13, 265–279. doi:
10.1097/01.gme.0000218683.97338.ea
Baley, J., and Li, J. (2012). MicroRNAs and ovarian function. J. Ovarian Res. 5:8.
doi: 10.1186/1757-2215-5-8
Bione, S., Benedetti, S., Goegan, M., Menditto, I., Marozzi, A., Ferrari, M., et al.
(2006). Skewed X-chromosome inactivation is not associated with premature
ovarian failure in a large cohort of Italian patients. Am. J. Med. Genet. A 140,
1349–1351. doi: 10.1002/ajmg.a.31312
Brown, W. T., Houck, G. E. Jr., Jeziorowska, A., Levinson, F. N., Ding, X.,
Dobkin, C., et al. (1993). Rapid fragile X carrier screening and prena-
tal diagnosis using a nonradioactive PCR test [published erratum appears
in JAMA 1994 Jan 5;271(1):28]. J. Am. Med. Assoc. 270, 1569–1575. doi:
10.1001/jama.1993.03510130075034
Bussani, C., Papi, L., Sestini, R., Baldinotti, F., Bucciantini, S., Bruni, V.,
et al. (2004). Premature ovarian failure and fragile X premutation: a study
on 45 women. Eur. J. Obstet. Gynecol. Reprod. Biol. 112, 189–191. doi:
10.1016/j.ejogrb.2003.06.003
Cronister, A., Teicher, J., Rohlfs, E. M., Donnenfeld, A., and Hallam, S.
(2008). Prevalence and instability of fragile X alleles: implications for
offering fragile X prenatal diagnosis. Obstet. Gynecol. 111, 596–601. doi:
10.1097/AOG.0b013e318163be0b
De Caro, J. J., Dominguez, C., and Sherman, S. L. (2008). Reproductive health of
adolescent girls who carry the fmr1 premutation: expected phenotype based on
current knowledge of fragile x-associated primary ovarian insufficiency. Ann.
N.Y. Acad. Sci. 1135, 99–111. doi: 10.1196/annals.1429.029
Ennis, S., Ward, D., and Murray, A. (2006). Nonlinear association between CGG
repeat number and age of menopause in FMR1 premutation carriers. Eur. J.
Hum. Genet. 14, 253–255. doi: 10.1038/sj.ejhg.5201510
Gallagher, J. C. (2007). Effect of early menopause on bone mineral density and
fractures. Menopause 14, 567–571. doi: 10.1097/gme.0b013e31804c793d
Garcia-Alegria, E., Ibanez, B., Minguez, M., Poch, M., Valiente, A., Sanz-Parra, A.,
et al. (2007). Analysis of FMR1 gene expression in female premutation carri-
ers using robust segmented linear regression models. RNA 13, 756–762. doi:
10.1261/rna.206307
Gonzalez-Perez, A., and Lopez-Bigas, N. (2011). Improving the assessment of
the outcome of nonsynonymous SNVs with a consensus deleteriousness score,
Condel. Am. J. Hum. Genet. 88, 440–449. doi: 10.1016/j.ajhg.2011.03.004
Hagerman, R. J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., et al.
(2001). Intention tremor, parkinsonism, and generalized brain atrophy in male
carriers of fragile X. Neurology 57, 127–130. doi: 10.1212/WNL.57.1.127
He, C., Kraft, P., Chen, C., Buring, J. E., Pare, G., Hankinson, S. E., et al. (2009).
Genome-wide association studies identify loci associated with age at menarche
and age at natural menopause. Nat. Genet. 41, 724–728. doi: 10.1038/ng.385
Hundscheid, R. D., Braat, D. D., Kiemeney, L. A., Smits, A. P., and Thomas, C.
M. (2001). Increased serum FSH in female fragile X premutation carriers with
either regular menstrual cycles or on oral contraceptives. Hum. Reprod. 16,
457–462. doi: 10.1093/humrep/16.3.457
Hunter, J. E., Epstein, M. P., Tinker, S. W., Charen, K. H., and Sherman, S. L.
(2008). Fragile X-associated primary ovarian insufficiency: evidence for addi-
tional genetic contributions to severity. Genet. Epidemiol. 32, 553–559. doi:
10.1002/gepi.20329
Jacobsen, B. K., Heuch, I., and Kvale, G. (2003). Age at natural menopause and
all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am. J.
Epidemiol. 157, 923–929. doi: 10.1093/aje/kwg066
Janicki, S. C., and Schupf, N. (2010). Hormonal influences on cognition and
risk for Alzheimer’s disease. Curr. Neurol. Neurosci. Rep. 10, 359–366. doi:
10.1007/s11910-010-0122-6
Jin, P., Duan, R., Qurashi, A., Qin, Y., Tian, D., Rosser, T. C., et al. (2007). Pur alpha
binds to rCGG repeats and modulates repeat-mediated neurodegeneration in
a drosophila model of fragile X Tremor/Ataxia syndrome. Neuron 55, 556–564.
doi: 10.1016/j.neuron.2007.07.020
Kalantaridou, S. N., Naka, K. K., Papanikolaou, E., Kazakos, N., Kravariti, M., Calis,
K. A., et al. (2004). Impaired endothelial function in young women with prema-
ture ovarian failure: normalization with hormone therapy. J. Clin. Endocrinol.
Metab. 89, 3907–3913. doi: 10.1210/jc.2004-0015
Kenneson, A., Zhang, F., Hagedorn, C. H., andWarren, S. T. (2001). Reduced FMRP
and increased FMR1 transcription is proportionally associated with CGG repeat
number in intermediate-length and premutation carriers. Hum. Mol. Genet 10,
1449–1454. doi: 10.1093/hmg/10.14.1449
Lu, C., Lin, L., Tan, H., Wu, H., Sherman, S. L., Gao, F., et al. (2012). Fragile X
premutation RNA is sufficient to cause primary ovarian insufficiency in mice.
Hum. Mol. Genet. 21, 5039–5047. doi: 10.1093/hmg/dds348
Mallolas, J., Duran, M., Sanchez, A., Jimenez, D., Castellvi-Bel, S., Rife, M., et al.
(2001). Implications of the FMR1 gene in menopause: study of 147 Spanish
women. Menopause 8, 106–110. doi: 10.1097/00042192-200103000-00005
Mandon-Pepin, B., Touraine, P., Kuttenn, F., Derbois, C., Rouxel, A., Matsuda,
F., et al. (2008). Genetic investigation of four meiotic genes in women with
premature ovarian failure. Eur. J. Endocrinol. 158, 107–115. doi: 10.1530/EJE-
07-0400
Marozzi, A., Vegetti, W., Manfredini, E., Tibiletti, M. G., Testa, G., Crosignani,
P. G., et al. (2000). Association between idiopathic premature ovarian failure
and fragile X premutation. Hum. Reprod. 15, 197–202. doi: 10.1093/humrep/
15.1.197
Meadows, K. L., Pettay, D., Newman, J., Hersey, J., Ashley, A. E., and Sherman, S.
L. (1996). Survey of the fragile X syndrome and the fragile X E syndrome in a
special education needs population. Am. J. Med. Genet. 64, 428–433.
Mondul, A. M., Rodriguez, C., Jacobs, E. J., and Calle, E. E. (2005). Age at natural
menopause and cause-specific mortality. Am. J. Epidemiol. 162, 1089–1097. doi:
10.1093/aje/kwi324
Murray, A., Ennis, S., MacSwiney, F., Webb, J., and Morton, N. E. (2000).
Reproductive and menstrual history of females with fragile X expansions. Eur.
J. Hum. Genet. 8, 247–252. doi: 10.1038/sj.ejhg.5200451
Murray, A., Webb, J., Grimley, S., Conway, G., and Jacobs, P. (1998). Studies of
FRAXA and FRAXE in women with premature ovarian failure. J. Med. Genet.
35, 637–640. doi: 10.1136/jmg.35.8.637
Newhall, K. J., Criniti, A. R., Cheah, C. S., Smith, K. C., Kafer, K. E., Burkart, A. D.,
et al. (2006). Dynamic anchoring of PKA is essential during oocyte maturation.
Curr. Biol. 16, 321–327. doi: 10.1016/j.cub.2005.12.031
Nishimura, T., Sugiura, K., and Naito, K. (2013). A-kinase anchor protein 1
(AKAP1) regulates cAMP-dependent protein kinase (PKA) localization and is
involved in meiotic maturation of porcine oocytes. Biol. Reprod. 88, 85. doi:
10.1095/biolreprod.112.106351
Peprah, E., He, W., Allen, E., Oliver, T., Boyne, A., and Sherman, S. L. (2010).
Examination of FMR1 transcript and protein levels among 74 premutation
carriers. J. Hum. Genet. 55, 66–68. doi: 10.1038/jhg.2009.121
Perry, J. R., Corre, T., Esko, T., Chasman, D. I., Fischer, K., Franceschini, N.,
et al. (2013). A genome-wide association study of early menopause and the
combined impact of identified variants. Hum. Mol. Genet. 22, 1465–1472. doi:
10.1093/hmg/dds551
Rae, J. M., Johnson, M. D., Scheys, J. O., Cordero, K. E., Larios, J. M., and Lippman,
M. E. (2005). GREB 1 is a critical regulator of hormone dependent breast cancer
growth. Breast Cancer Res. Treat. 92, 141–149. doi: 10.1007/s10549-005-1483-4
Rodriguez-Revenga, L., Madrigal, I., Badenas, C., Xuncla,M., Jimenez, L., andMila,
M. (2009). Premature ovarian failure and fragile X female premutation carriers:
no evidence for a skewed X-chromosome inactivation pattern. Menopause 16,
944–949. doi: 10.1097/gme.0b013e3181a06a37
Rohr, J., Allen, E. G., Charen, K., Giles, J., He, W., Dominguez, C., et al. (2008).
Anti-Mullerian hormone indicates early ovarian decline in fragile X mental
retardation (FMR1) premutation carriers: a preliminary study. Hum. Reprod.
23, 1220–1225. doi: 10.1093/humrep/den050
Schwartz, C. E., Dean, J., Howard-Peebles, P. N., Bugge, M., Mikkelsen, M.,
Tommerup, N., et al. (1994). Obstetrical and gynecological complications in
fragile X carriers: a multicenter study. Am. J. Med. Genet. 51, 400–402. doi:
10.1002/ajmg.1320510419
Sellier, C., Freyermuth, F., Tabet, R., Tran, T., He, F., Ruffenach, F., et al. (2013).
Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters
microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep.
3, 869–880. doi: 10.1016/j.celrep.2013.02.004
Sellier, C., Rau, F., Liu, Y., Tassone, F., Hukema, R. K., Gattoni, R., et al.
(2010). Sam68 sequestration and partial loss of function are associated
with splicing alterations in FXTAS patients. EMBO J. 29, 1248–1261. doi:
10.1038/emboj.2010.21
Seltzer, M. M., Baker, M. W., Hong, J., Maenner, M., Greenberg, J., and Mandel, D.
(2012). Prevalence of CGG expansions of the FMR1 gene in a US population-
based sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 589–597. doi:
10.1002/ajmg.b.32065
www.frontiersin.org August 2014 | Volume 5 | Article 260 | 7
Allen et al. Genetic modifiers of FXPOI
Shen, C., Delahanty, R. J., Gao, Y. T., Lu, W., Xiang, Y. B., Zheng, Y., et al. (2013).
Evaluating GWAS-identified SNPs for age at natural menopause among chinese
women. PLoS ONE 8:e58766. doi: 10.1371/journal.pone.0058766
Sherman, S. L. (2000). Seminars in genetics: premature ovarian failure in the
fragile X syndrome. Am. J. Med. Genet. 97 189–195. doi: 10.1002/1096-
8628(200023)97:3&lt;189::AID-AJMG1036&gt;3.0.CO;2-J
Siepel, A., Bejerano, G., Pedersen, J. S., Hinrichs, A. S., Hou, M., Rosenbloom, K.,
et al. (2005). Evolutionarily conserved elements in vertebrate, insect, worm, and
yeast genomes. Genome Res. 15, 1034–1050. doi: 10.1101/gr.3715005
Sofola, O. A., Jin, P., Qin, Y., Duan, R., Liu, H., De Haro, M., et al. (2007).
RNA-binding proteins hnRNPA2/B1 and CUGBP1 suppress fragile X CGG pre-
mutation repeat-induced neurodegeneration in a Drosophila model of FXTAS.
Neuron 55, 565–571. doi: 10.1016/j.neuron.2007.07.021
Spath, M. A., Feuth, T. B., Allen, E. G., Smits, A. P., Yntema, H. G., van Kessel, A. G.,
et al. (2011a). Intra-individual stability over time of standardized anti-Mullerian
hormone in FMR1 premutation carriers. Hum. Reprod. 26, 2185–2191. doi:
10.1093/humrep/der146
Spath, M. A., Feuth, T. B., Smits, A. P., Yntema, H. G., Braat, D. D.,
Thomas, C. M., et al. (2011b). Predictors and risk model development for
menopausal age in fragile X premutation carriers. Genet. Med. 13, 643–650. doi:
10.1097/GIM.0b013e31821705e5
Spath, M. A., Nillesen, W. N., Smits, A. P., Feuth, T. B., Braat, D. D., van Kessel, A.
G., et al. (2010). X chromosome inactivation does not define the development of
premature ovarian failure in fragile X premutation carriers. Am. J. Med. Genet.
A 152A, 387–393. doi: 10.1002/ajmg.a.33243
Stolk, L., Perry, J. R., Chasman, D. I., He, C., Mangino, M., Sulem, P., et al.
(2012). Meta-analyses identify 13 loci associated with age at menopause and
highlight DNA repair and immune pathways. Nat. Genet. 44, 260–268. doi:
10.1038/ng.1051
Stolk, L., Zhai, G., van Meurs, J. B., Verbiest, M. M., Visser, J. A., Estrada, K., et al.
(2009). Loci at chromosomes 13, 19 and 20 influence age at natural menopause.
Nat. Genet. 41, 645–647. doi: 10.1038/ng.387
Sullivan, A. K., Marcus, M., Epstein, M. P., Allen, E. G., Anido, A. E., Paquin, J. J.,
et al. (2005). Association of FMR1 repeat size with ovarian dysfunction. Hum.
Reprod. 20, 402–412. doi: 10.1093/humrep/deh635
Sullivan, S. D., Welt, C., and Sherman, S. (2011). FMR1 and the continuum of
primary ovarian insufficiency. Semin. Reprod. Med. 29, 299–307. doi: 10.1055/s-
0031-1280915
Tassone, F., Beilina, A., Carosi, C., Albertosi, S., Bagni, C., Li, L., et al. (2007).
Elevated FMR1mRNA in premutation carriers is due to increased transcription.
RNA 13, 555–562. doi: 10.1261/rna.280807
Tejada, M. I., Garcia-Alegria, E., Bilbao, A., Martinez-Bouzas, C., Beristain,
E., Poch, M., et al. (2008). Analysis of the molecular parameters that
could predict the risk of manifesting premature ovarian failure in female
premutation carriers of fragile X syndrome. Menopause 15, 945–949. doi:
10.1097/gme.0b013e3181647762
van der Stege, J. G., Groen, H., van Zadelhoff, S. J., Lambalk, C. B., Braat,
D. D., van Kasteren, Y. M., et al. (2008). Decreased androgen concentra-
tions and diminished general and sexual well-being in women with pre-
mature ovarian failure. Menopause 15, 23–31. doi: 10.1097/gme.0b013e318
0f6108c
Welt, C. K. (2008). Primary ovarian insufficiency: a more accurate term for prema-
ture ovarian failure. Clin. Endocrinol. (Oxf.) 68, 499–509. doi: 10.1111/j.1365-
2265.2007.03073.x
Welt, C. K., Smith, P. C., and Taylor, A. E. (2004). Evidence of early ovarian aging
in fragile X premutation carriers. J. Clin. Endocrinol. Metab. 89, 4569–4574. doi:
10.1210/jc.2004-0347
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 15 May 2014; accepted: 14 July 2014; published online: 07 August 2014.
Citation: Allen EG, Grus WE, Narayan S, Espinel W and Sherman SL (2014)
Approaches to identify genetic variants that influence the risk for onset of fragile X-
associated primary ovarian insufficiency (FXPOI): a preliminary study. Front. Genet.
5:260. doi: 10.3389/fgene.2014.00260
This article was submitted to Genetic Disorders, a section of the journal Frontiers in
Genetics.
Copyright © 2014 Allen, Grus, Narayan, Espinel and Sherman. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permit-
ted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Genetics | Genetic Disorders August 2014 | Volume 5 | Article 260 | 8
